Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

2021216 citationsJournal Articlebronze Open Access

Authors

Daniel J. Olson · University of Chicago

Zeynep Eroglu · Moffitt Cancer Center

Bruce Brockstein · NorthShore University HealthSystem

Andrew Poklepovic · Virginia Cancer Institute

Madhuri Bajaj · Illinois CancerCare

Sunil Babu · Fort Wayne Medical Institute

Sigrun Hallmeyer ·

Abstract

To our knowledge, this is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.

Topics & Keywords

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 39, Issue 24, pp. 2647-2655

DOI: 10.1200/jco.21.00079

Field-Weighted Citation Impact: 14.66